B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
JBIO
Jade BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that JADE101 delivers credible Phase 1 biomarker and PK data in Q2 2026, enabling a clean transition into IgAN patient studies while JADE201 also enters the clinic on schedule. If Jade executes on both assets, investors may start valuing it as a multi-program autoimmune platform with enough capital to reach several inflection points.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +16.5.
What can break
Early biomarker success in healthy volunteers may not translate into patient efficacy in IgAN or other autoimmune indications.
Momentum
58
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00Analysis 2026-04-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $49.89
Why
Momentum58 · Δ7d +6.4
Value41 · Δ7d 0.0
Sentiment77 · Δ7d +16.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +16.5.
Contradictions & invalidation
- • Early biomarker success in healthy volunteers may not translate into patient efficacy in IgAN or other autoimmune indications.
- • JADE101 interim data may be delayed, clinically ambiguous, or fail to support the intended dosing profile.
- • The bear case is that JBIO still has no efficacy data, no revenue, and a thesis dominated by timeline promises.
Catalyst clock
2026-06-30
JADE101 Phase 1 interim biomarker data is the key near-term proof point
Lead driver: Sentiment · See AI snapshot
Momentum
58
9% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
-27.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
77
62% active weight
Current posture
7d trendImproving
Δ7d
+16.5
Δ21d
+26.3
Why this grade
Composite grade B. Momentum 58.4 / Value 41.2 / Sentiment 77.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.49B
Beta
0.88
Shares Out
63.6M
P/E (TTM) · Derived
-5.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.88
Rev YoY
-
EPS YoY
-33.0%
Gross Margin
-
Op Margin
-
Net Debt
-$335.43M
Current Ratio
14.93
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data